✦ LIBER ✦

Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

✍ Scribed by Skali, Hicham; Lin, Julie; Pfeffer, Marc A.; Chen, Chao-Yin; Cooper, Mark E.; McMurray, John J.V.; Nissenson, Allen R.; Remuzzi, Giuseppe; Rossert, Jerome; Parfrey, Patrick S.; Scott-Douglas, Nairne W.; Singh, Ajay K.; Toto, Robert; Uno, Hajime; Ivanovich, Peter

Book ID: 123364454
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 550 KB
Volume: 61
Category: Article
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2012.08.043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictors of fatal and nonfatal cardiov

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

✍ John J.V. McMurray; Hajime Uno; Petr Jarolim; Akshay S. Desai; Dick de Zeeuw; Ka 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 463 KB

Mitigating the Cardiovascular Risk of An

Mitigating the Cardiovascular Risk of Anemia in Patients with Type 2 Diabetes and CKD: Does Darbepoetin Help? The TREAT Trial

✍ Christi Hayes; Anis Alam; Julie Black-Peart; Samy I. McFarlane 📂 Article 📅 2010 🏛 Current Science Inc. 🌐 English ⚖ 71 KB

Impact of metabolic syndrome and its com

Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

✍ Russell Scott; Mark Donoghoe; Gerald F Watts; Richard O’Brien; Christopher Pardy 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 177 KB

Hemoglobin A1cvariability as an independ

Hemoglobin A1cvariability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study

✍ Penno, Giuseppe; Solini, Anna; Zoppini, Giacomo; Orsi, Emanuela; Fondelli, Cecil 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 232 KB

Evaluation of the dual peroxisome prolif

Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial

✍ Lincoff, A. Michael; Tardif, Jean-Claude; Neal, Bruce; Nicholls, Stephen J.; Ryd 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Trial finds low dose ramipril does not r

Trial finds low dose ramipril does not reduce cardiovascular or renal events in people with type 2 diabetes and albuminuria: Abstracted from: Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328(7438): 495–500.

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 125 KB